All Focus Shifts To Bionomics’ PTSD Study After Anxiety Trial Disappoints – Bionomics (NASDAQ:BNOX)
[ad_1] Bionomics Limited BNOX announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD), showing a miss on the primary endpoint. HC…